Segmentation by type differentiates the technological approaches underpinning the Knee Cartilage Repair market into four categories: Cell‑based therapies, Scaffold‑based implants, Biologic injections, and Surgical techniques. Cell‑based therapies, such as autologous chondrocyte implantation, capture roughly 30 % of market value due to their regenerative potential and high procedural cost. Scaffold‑based implants, including synthetic and natural matrices, hold about 25 % of the market, favored for their structural support and off‑the‑shelf availability. Biologic injections—e.g., platelet‑rich plasma and stem‑cell suspensions—represent 20 % of revenue, reflecting growing outpatient adoption and lower procedural barriers. Surgical techniques, such as microfracture and osteochondral autograft transfer, command the remaining 25 %, driven by their established clinical track record and lower upfront technology investment. This type‑based taxonomy clarifies how each modality contributes to total market size through distinct cost structures, adoption rates, and reimbursement landscapes.